Biodexa's mx-110 continues to show promise in recurrent glioblastoma (rgbm), the deadliest brain cancer

In a small but important phase 1 study, mtx110 is outperforming historic norms of progression free and overall survival cardiff, uk / accesswire / october 17, 2024 / biodexa pharmaceuticals plc (nasdaq:bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, released positive patient updates on progression-free survival (pfs) and overall survival (os) from the ongoing magic-1 study of mtx110 in recurrent glioblastoma (rgbm), a lethal form of adult brain cancer. the study (nct05324501) is designed to evaluate the feasibility, safety and efficacy of treating rgbm patients with mtx110.
BDRX Ratings Summary
BDRX Quant Ranking